Inclusion Criteria:  Age 18 to 80 years; Subject has solitary intracranial unruptured aneurysms located in Vertebral artery(VA) or Internal Carotid Artery(ICA) diagnosed by DSA; The neck width of the aneurysm ≥4 mm or the body-neck-rato <2, the max diameter of the aneurysm body ≤10 mm; The diameter of the target vessel is 2.0 to 6.5mm; Subject or legal representative is able to understand the purpose of study, agrees to comply with protocol requirements and has provided written informed consent.  Exclusion Criteria:  Aneurysmal associated arteriovenous malformation. Subject had a subarachnoid hemorrhage within 30 days prior to the enrollment date. Modified Rankin Scale(mRS) score ≥3 Platelet(PLT)<60*10^9/L or International Normalized Ratio(INR)>1.5 Heart, lung, liver, kidney failure or other serious diseases (such as brain tumors, systemic infection, active disseminated intravascular coagulation, myocardial infarction within 12 months before enrollment, history of severe mental illness, severe narrowing or occlusion of the feeding artery); Lesions judged by researchers that are not suitable for stent delivery and deployment (such as severe stenosis of the tumor-bearing artery, too tortuous tumor-bearing artery, and the stent cannot reach the lesion, stent in the target artery. etc.) Have undergone major surgery within 30 days before enrollment or plan to undergo surgery within 180 days after enrollment. History of allergies to antiplatelet drugs, anticoagulants, anesthetics, contrast agents. History of allergies to platinum and tungsten. Expected life <12 months. Female subjects who are pregnant or lactating within the study period. Subject has participated in any other drug or medical device clinical investigations in 1 month before signing informed consent . Other circumstances judged by researchers that are not suitable for enrollment .